Past, present and future targets for immunotherapy in ovarian cancer

Immunotherapy

Volumn 6, Issue 12, 2014, Pages 1279-1293

  Schwab, Carlton L ^a   English, Diana P ^a   Roque, Dana M ^a   Pasternak, Monica ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adoptive transfer; CA125; EpCAM; mesothelin; NY ESO 1; ovarian cancer; p53; tumor associated antigens; tumor vaccines; WT 1

Indexed keywords

ABAGOVOMAB; AMATUXIMAB; BAY 94 9343; BEVACIZUMAB; BMS 936559; CA 125 ANTIGEN; CARBOPLATIN; CATUMAXOMAB; CD3 ANTIBODY; CRS 207; CYCLOPHOSPHAMIDE; DRUG ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; FLUDARABINE; IPILIMUMAB; MESOTHELIN; NIVOLUMAB; NY ESO 1 ANTIGEN; OREGOVOMAB; PACLITAXEL; PLACEBO; PROTEIN P53; PSEUDOMONAS EXOTOXIN; TUMOR CELL VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; VASCULOTROPIN RECEPTOR; WT1 PROTEIN;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL LYSATE; CELL THERAPY; DRUG TARGETING; EMBRYONIC STEM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; OVARY CANCER; PASSIVE IMMUNIZATION; REVIEW; T LYMPHOCYTE; ANIMAL; CLINICAL TRIAL (TOPIC); FEMALE; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; RECURRENT DISEASE; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; RECURRENCE;

EID: 84919785847     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.90     Document Type: Review

References (135)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012).
2. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
4. Lu J, Aggarwal R, Kanji S et al. Human ovarian tumor cells escape gammadelta Tcell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules. PLoS ONE 6(9), e23348 (2011).
5. Thedrez A, Sabourin C, Gertner J et al. Self/non-self discrimination by human gamma delta Tcells: simple solutions for a complex issue? Immunol. Rev. 215, 123-135 (2007).
6. Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104(9), 3360-3365 (2007).
7. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl Acad. Sci. USA 107(17), 7875-7880 (2010).
8. Krockenberger M, Dombrowski Y, Weidler C et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J. Immunol. 180(11), 7338-7348 (2008).
9. +/regulatory Tcell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102(51), 18538-18543 (2005).
10. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory Tcells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004).
11. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 106(2), 584-592 (2005).
12. Matte I, Lane D, Boivin M, Rancourt C, Piche A. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer 14(1), 234 (2014).
13. + T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18(12), 3281-3292 (2012).
14. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615 (2011).
15. Tothill RW, Tinker AV, George J et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14(16), 5198-5208 (2008).
16. Lichtenstein A, Kahle J. Anti-tumor effect of inflammatory neutrophils: characteristics of invivo generation and invitro tumor cell lysis. Int. J. Cancer 35(1), 121-127 (1985).
17. Gall S, Bundy B, Beecham J et al. Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus Corynebacterium parvum (a Gynecologic Oncology Group Study). Gynecol. Oncol. 25(1), 26-36 (1986).
18. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl. Immunohistochem. Mol. Morphol. 13(3), 243-247 (2005).
19. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int. J. Cancer 50(3), 373-381 (1992).
20. Le DT, Brockstedt DG, Nir-Paz R et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin. Cancer Res. 18(3), 858-868 (2012).
21. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol. Cancer. Ther. 11(3), 517-525 (2012).
22. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44(1), 46-53 (2008).
23. Odunsi K, Jungbluth AA, Stockert E et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 63(18), 6076-6083 (2003).
24. Jager E, Karbach J, Gnjatic S et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl Acad. Sci. USA 103(39), 14453-14458 (2006).
25. Odunsi K, Matsuzaki J, Karbach J et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc. Natl Acad. Sci. USA 109(15), 5797-5802 (2012).
26. Odunsi K, Matsuzaki J, James SR et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol. Res. 2(1), 37-49 (2014).
27. Hung CF, Wu TC, Monie A, Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol. Rev. 222, 43-69 (2008).
28. +) Tcell responses to HLA class I-restricted wild-type sequence p53 peptides. Clin. Immunol. 125(1), 43-51 (2007).
29. Goodell V, Salazar LG, Urban N et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J. Clin. Oncol. 24(5), 762-768 (2006).
30. Rahma OE, Ashtar E, Czystowska M et al. A Gynecologic Oncology group PhaseII trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunl. Immunother. 61(3), 373-384 (2012).
31. Nakatsuka S, Oji Y, Horiuchi T et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod. Pathol. 19(6), 804-814 (2006).
32. Pils D, Pinter A, Reibenwein J et al. In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. Br. J. Cancer 96(3), 485-491 (2007).
33. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107(4), 477-484 (2001).
34. Oka Y, Tsuboi A, Murakami M et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78(1), 56-61 (2003).
35. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101(38), 13885-13890 (2004).
36. Tsuboi A, Oka Y, Osaki T et al. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol. Immunol. 48(3), 175-184 (2004).
37. Izumoto S, Tsuboi A, Oka Y et al. PhaseII clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J. Neurosurg. 108(5), 963-971 (2008).
38. Ohno S, Kyo S, Myojo S et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res. 29(11), 4779-4784 (2009).
39. Dohi S, Ohno S, Ohno Y et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Res. 31(7), 2441-2445 (2011).
40. Vermeij R, Daemen T, De Bock GH et al. Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin. Dev. Immunol. doi: 10.1155/2010/891505. (2010) (Epub ahead of print).
41. Zhao X, Wei YQ, Peng ZL. Induction of Tcell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol. Invest. 30(1), 33-45 (2001).
42. Hernando JJ, Park TW, Kubler K, Offergeld R, Schlebusch H, Bauknecht T. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a Phase I trial. Cancer Immunol. Immunother. 51(1), 45-52 (2002).
43. Kandalaft LE, Chiang CL, Tanyi J et al. A PhaseI vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J. Transl. Med. 11, 149 (2013).
44. He QZ, Luo XZ, Wang K et al. Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas Cell. Physiol. Biochem. 33(1), 173-184 (2014).
45. Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target? J. Natl Cancer Inst. 96(8), 583-585 (2004).
46. Aguilar-Gallardo C, Simon C. Cells, stem cells, and cancer stem cells. Semin. Reprod. Med. 31(1), 5-13 (2013).
47. Zhang Z, Chen X, Chang X, Ye X, Li Y, Cui H. Vaccination with embryonic stem cells generates effective antitumor immunity against ovarian cancer. Int. J. Mol. Med. 31(1), 147-153 (2013).
48. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975).
49. Dangaj D, Scholler N. Blocking the B7-H4 pathway with novel recombinant antibodies enhances Tcell-mediated antitumor responses. Oncoimmunology 2(8), e25913 (2013).
50. Zhang L, Wu H, Lu D et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene 32(46), 5347-5358 (2013).
51. Litvinov SV, Bakker HA, Gourevitch MM, Velders MP, Warnaar SO. Evidence for a role of the epithelial glycoprotein40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes. Commun. 2(5), 417-428 (1994).
52. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356(9246), 1981-1982 (2000).
53. Spizzo G, Went P, Dirnhofer S et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol. Oncol. 103(2), 483-488 (2006).
54. Kobel M, Kalloger SE, Boyd N et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5(12), e232 (2008).
55. Bellone S, Siegel ER, Cocco E et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int. J. Gynecol. Cancer 19(5), 860-866 (2009).
56. Shetye J, Frodin JE, Christensson B et al. Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A). Cancer Immunol. Immunother. 27(2), 154-162 (1988).
57. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98(8), 2526-2534 (2001).
58. Zeidler R, Mysliwietz J, Csanady M et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br. J. Cancer 83(2), 261-266 (2000).
59. Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res. 72(16), 3958-3966 (2012).
60. Heiss MM, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized Phase II/III trial. Int. J. Cancer 127(9), 2209-2221 (2010).
61. Walter M. Fiedler MW, Maxim Kebenko et al. A Phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. Oral Abstract Session, Developmental Therapeutics - Clinical Pharmacology and Immunotherapy. Presented at: 2012 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June2012
62. Burges A, Wimberger P, Kumper C et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a Phase I/II study. Clin. Cancer Res. 13(13), 3899-3905 (2007).
63. Bast RC, Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 116(12), 2850-2853 (2010).
64. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J. Clin. Oncol. 19(20), 4054-4057 (2001).
65. Patankar MS, Jing Y, Morrison JC et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol. Oncol. 99(3), 704-713 (2005).
66. Wagner U, Schlebusch H, Kohler S, Schmolling J, Grunn U, Krebs D. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma 16(1), 33-40 (1997).
67. Reinartz S, Boerner H, Koehler S, Von Ruecker A, Schlebusch H, Wagner U. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines - a preliminary report. Hybridoma 18(1), 41-45 (1999).
68. Reinartz S, Kohler S, Schlebusch H et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin. Cancer Res. 10(5), 1580-1587 (2004).
69. Pfisterer J, Du Bois A, Sehouli J et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A Phase I trial of the AGO-OVAR. Ann. Oncol. 17(10), 1568-1577 (2006).
70. Sabbatini P, Harter P, Scambia G et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a Phase III trial of the AGO OVAR, COGI, GINECO, and GEICO - the MIMOSA study. J. Clin. Oncol. 31(12), 1554-1561 (2013).
71. Mobus VJ, Baum RP, Bolle M et al. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am. J. Obstet. Gynecol. 189(1), 28-36 (2003).
72. Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B and Tcell responses in patients injected with MAb-B43.13-evidence for antibody-mediated antigen-processing and presentation of CA125 invivo. Cancer Biother. Radiopharm. 16(3), 187-203 (2001).
73. Braly P, Nicodemus CF, Chu C et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized Phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J. Immunother. 32(1), 54-65 (2009).
74. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory Tcells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56(5), 641-648 (2007).
75. Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med. Chem. 13(2), 276-280 (2013).
76. Golfier S, Kopitz C, Kahnert A et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol. Cancer Ther. 13(6), 1537-48 (2014).
77. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562 (2004).
78. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. 54(6), 369-377 (2005).
79. Barnett JC, Bean SM, Whitaker RS et al. Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol. Oncol. 116(3), 556-562 (2010).
80. Vasievich EA, Huang L. The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol. Pharm. 8(3), 635-641 (2011).
81. + human regulatory Tcells invivo: kinetics of Treg depletion and alterations in immune functions invivo and invitro. Int. J. Cancer 120(12), 2723-2733 (2007).
82. Hoos A, Ibrahim R, Korman A et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 37(5), 533-546 (2010).
83. + regulatory Tcell function. Science 322(5899), 271-275 (2008).
84. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24(15), 2283-2289 (2006).
85. Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS ONE 9(2), e89350 (2014).
86. Bagnoli M, Canevari S, Figini M et al. A step further in understanding the biology of the folate receptor in ovarian carcinoma. Gynecol. Oncol. 88(1 Pt 2), S140-S144 (2003).
87. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol. Oncol. 129(3), 452-458 (2013).
88. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the Tcell response. Nat. Rev. Immunol. 12(4), 269-281 (2012).
89. Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233-5239 (2008).
90. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114(8), 1545-1552 (2009).
91. Cocco C, Pistoia V, Airoldi I. New perspectives for melanoma immunotherapy: role of IL-12. Curr. Mol. Med. 9(4), 459-469 (2009).
92. Chiriva-Internati M, Weidanz JA, Yu Y et al. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J. Immunother. 31(8), 693-703 (2008).
93. Bellone S, Anfossi S, O'brien TJ et al. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Cancer 115(4), 800-811 (2009).
94. Aoki Y, Takakuwa K, Kodama S et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res. 51(7), 1934-1939 (1991).
95. Fujita K, Ikarashi H, Takakuwa K et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin. Cancer Res. 1(5), 501-507 (1995).
96. Dobrzanski MJ, Rewers-Felkins KA, Quinlin IS et al. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin. Immunol. 133(3), 333-352 (2009).
97. Wright SE, Rewers-Felkins KA, Quinlin IS et al. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J. Immunother. 35(2), 196-204 (2012).
98. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86(24), 10024-10028 (1989).
99. Chekmasova AA, Brentjens RJ. Adoptive Tcell immunotherapy strategies for the treatment of patients with ovarian cancer. Discov. Med. 9(44), 62-70 (2010).
100. Hwu P, Yang JC, Cowherd R etal. In vivo antitumor activity of Tcells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55(15), 3369-3373 (1995).
101. Parker LL, Do MT, Westwood JA et al. Expansion and characterization of Tcells transduced with a chimeric receptor against ovarian cancer. Hum. Gene Ther. 11(17), 2377-2387 (2000).
102. Westwood JA, Smyth MJ, Teng MW et al. Adoptive transfer of Tcells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc. Natl Acad. Sci. USA 102(52), 19051-19056 (2005).
103. Westwood JA, Murray WK, Trivett M et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J. Immunother. 32(3), 292-301 (2009).
104. Yoon SH, Lee JM, Cho HI et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther. 16(6), 489-497 (2009).
105. Parente-Pereira AC, Whilding LM, Brewig N et al. Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted Tcells combined with carboplatin. J. Immunol. 191(5), 2437-2445 (2013).
106. Chekmasova AA, Rao TD, Nikhamin Y et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of Tcells genetically targeted to the MUC16 antigen. Clin. Cancer Res. 16(14), 3594-3606 (2010).
107. Stauss HJ, Thomas S, Cesco-Gaspere M et al. WT1-specific T cell receptor gene therapy: improving TCR function in transduced Tcells. Blood Cells Mol. Dis. 40(1), 113-116 (2008).
108. Hong H, Stastny M, Brown C et al. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J. Immunother. 37(2), 93-104 (2014).
109. Kershaw MH, Westwood JA, Parker LL et al. A Phase I study on adoptive immunotherapy using gene-modified Tcells for ovarian cancer. Clin. Cancer Res. 12(20 Pt 1), 6106-6115 (2006).
110. Brenner MK. Will T-cell therapy for cancer ever be a standard of care? Cancer Gene Ther. 19(12), 818-821 (2012).
111. Kandalaft LE, Powell DJ, Jr., Coukos G. A Phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous Tcells for recurrent ovarian cancer. J. Transl. Med. 10, 157 (2012).
112. Song DG, Ye Q, Carpenito C etal. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71(13), 4617-4627 (2011).
113. Wertel I, Barczynski B, Kotarski J. The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment. Front. Biosci. 13, 2177-2190 (2008).
114. Bol KF, Tel J, De Vries IJ, Figdor CG. Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology 2(3), e23431 (2013).
115. Satoh Y, Esche C, Gambotto A et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J. Exp. Ther. Oncol. 2(6), 337-349 (2002).
116. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 59(16), 4035-4041 (1999).
117. You CX, Shi M, Liu Y, Cao M, Luo R, Hermonat PL. AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: evidence for IL-12 intracrine activity in DC. Oncoimmunology 1(6), 847-855 (2012).
118. Yang SC, Hillinger S, Riedl K et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin. Cancer Res. 10(8), 2891-2901 (2004).
119. Hu J, Yuan X, Belladonna ML et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 66(17), 8887-8896 (2006).
120. Ishida T, Chada S, Stipanov M et al. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin. Exp. Immunol. 117(2), 244-251 (1999).
121. Ribas A, Butterfield LH, Hu B et al. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J. Immunother. 23(1), 59-66 (2000).
122. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol. 165(10), 5713-5719 (2000).
123. Wan Y, Emtage P, Zhu Q et al. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell. Immunol. 198(2), 131-138 (1999).
124. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells invitro and invivo. J. Exp. Med. 184(2), 465-472 (1996).
125. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186(7), 1177-1182 (1997).
126. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60(4), 1028-1034 (2000).
127. Bonifaz LC, Bonnyay DP, Charalambous A etal. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves Tcell vaccination. J. Exp. Med. 199(6), 815-824 (2004).
128. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ Tcell tolerance. J. Exp. Med. 196(12), 1627-1638 (2002).
129. Tacken PJ, De Vries IJ, Gijzen K et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106(4), 1278-1285 (2005).
130. Vacchelli E, Vitale I, Eggermont A et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2(10), e25771 (2013).
131. Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labbe J, Bonnotte B. Dendritic cell-tumor cell hybrids and immunotherapy: what's next? Cytotherapy 13(7), 774-785 (2011).
132. Sukhorukov VL, Reuss R, Endter JM et al. A biophysical approach to the optimisation of dendritic-tumour cell electrofusion. Biochem. Biophys. Res. Commun. 346(3), 829-839 (2006).
133. Chu CS, Boyer J, Schullery DS et al. PhaseI/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol. Immunother. 61(5), 629-641 (2012).
134. Loveland BE, Zhao A, White S et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 12(3 Pt 1), 869-877 (2006).
135. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews. Cancer 12(4), 252-264 (2012).